Your browser doesn't support javascript.
loading
Pilot testing a patient decision aid as a strategy to reduce overtreatment for older women with early-stage breast cancer.
Pesavento, Cecilia M; Kazemi, Ruby J; Kappelman, Abigail; Thompson, Jessica L; Jobin, Chad; Wang, Ton; Dossett, Lesly A.
Afiliação
  • Pesavento CM; University of Michigan Medical School, Ann Arbor, MI, USA; Vanderbilt University Medical Center, Department of Surgery, Nashville, TN, USA. Electronic address: ceciliapesavento@gmail.com.
  • Kazemi RJ; University of Michigan Medical School, Ann Arbor, MI, USA.
  • Kappelman A; University of Michigan Medical School, Ann Arbor, MI, USA; University of Michigan, Department of Epidemiology, Ann Arbor, MI, USA.
  • Thompson JL; Corewell Health West, Department of Cancer Health, Grand Rapids, MI, USA.
  • Jobin C; Michigan Medicine, Ann Arbor, MI, USA.
  • Wang T; Duke University School of Medicine, Department of Surgery, Durham, NC, USA.
  • Dossett LA; University of Michigan, Center for Healthcare Outcomes and Policy, Ann Arbor, MI, USA; University of Michigan, Department of Surgery, Ann Arbor, MI, USA.
Am J Surg ; 235: 115774, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38834420
ABSTRACT

BACKGROUND:

Despite national guidelines recommending omission of sentinel lymph node biopsy (SLNB) and post-lumpectomy radiotherapy (RT) in older women with early-stage, hormone receptor-positive (HR+) breast cancer, these practices persist. This pilot study assesses whether a decision aid can target patient-level determinants of low-value treatments.

METHODS:

We adapted and pilot-tested a decision aid in women ≥70 years old with early-stage HR â€‹+ â€‹breast cancer. Primary outcomes included acceptability and appropriateness of the decision aid. Secondary outcomes included treatment choice and satisfaction with decision.

RESULTS:

Twenty-three patients enrolled in the trial. 19 completed survey one; 16 completed survey two. Primary outcomes demonstrated that 84% of patients agreed or strongly agreed the aid was acceptable and appropriate. Secondary outcomes demonstrated that 19% of patients underwent SLNB (below pre-intervention baseline), and 85% received adjuvant RT (change not statistically significant).

CONCLUSIONS:

We demonstrate that a decision aid may effectively target patient-level factors contributing to overuse of low-value therapies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Técnicas de Apoio para a Decisão / Biópsia de Linfonodo Sentinela / Sobretratamento Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Técnicas de Apoio para a Decisão / Biópsia de Linfonodo Sentinela / Sobretratamento Idioma: En Ano de publicação: 2024 Tipo de documento: Article